| Home Market Dynamics Sector Analysis Company Insights AI Investing Strategies Contact Us Login |
| Recent advancements in treatment efficacy, particularly the promising results from the Phase 3 MYR301 study, underscore Gilead Sciences' commitment to innovative solutions for challenging conditions such as chronic hepatitis delta virus. Additionally, the sustained treatment outcomes observed with Livdelzi mark significant progress in managing primary biliary cholangitis, reinforcing Gilead's role in enhancing patient care. These developments reflect a strong focus on effective therapeutic options and continuous improvement in patient outcomes. However, ongoing challenges in regulatory approvals and market competition may hinder the rapid integration of these innovations into everyday clinical practice. |
| The price action of Gilead Sciences (GILD) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The market sentiment at 0.5 is modestly bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.There is no clear direction for GILD since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 0.7, and the negative at -0.2 on 2025-05-07. The forces of and Valuation Sentiment (-1) will drive down the price. The forces of Stock Price Trend (0), Sector Price Trend (0), Price Level Sentiment (0), Option Sentiment (0), Market Risk Appetite (0), and Sentiment towards Fundamentals (3.9) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| GILD | |||||||||||||
| Date | Attention | Price | Price Level | Change | SMA10 Trend | Trend Sentiment | Hourly Trend | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-07 | 0%(0%) | 0 | 0% | 0.5 | 3.9 | -1 | |||||||
| 2025-05-06 | 0%(0%) | 0 | 0% | -0.2 | -0.3 | -1 | |||||||
| 2025-05-05 | 0%(0%) | 0 | 0% | -0.4 | -1.4 | -1 | |||||||
| 2025-05-04 | 0%(0%) | 0 | 0% | -0.7 | -2.9 | -1 | |||||||
| 2025-05-03 | 0%(0%) | 0 | 0% | -0.7 | -2.9 | -1 | |||||||
| 2025-05-02 | 0%(0%) | 0 | 0% | -0.7 | -2.9 | -1 | |||||||
| 2025-05-01 | 0%(0%) | 0 | 0% | -0.6 | -2.8 | -1 | |||||||
| 2025-04-30 | 0%(0%) | 0 | 0% | -0.7 | -3.1 | -1 | |||||||
| 2025-04-29 | 0%(0%) | 0 | 0% | -0.7 | -3.1 | -1 | |||||||
| 2025-04-28 | 0%(0%) | 0 | 0% | -0.8 | -3.5 | -1 | |||||||
| Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | |||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | |||||||||||||
| 2025-09-29 00:31:51 The sustained biochemical response reported with Livdelzi suggests a significant advancement in treatment options for patients with primary biliary cholangitis. |
| 2025-09-29 00:31:51 Gilead's ongoing investments in R&D signal a trend towards prioritizing innovative treatment solutions and maintaining leadership in the biopharmaceutical industry. |
| 2025-09-29 00:31:51 The efficacy and safety of Livdelzi in various treatment histories affirm its potential for regulatory approval, contributing to Gilead's competitive position in the market. |
| 2025-09-29 00:31:51 The positive results from the Phase 3 MYR301 study indicate the efficacy of bulevirtide in maintaining virologic suppression, showcasing advancements in treatment for chronic hepatitis delta virus. |
| 2025-09-29 00:31:51 Gilead Sciences' announcement of $11 billion in new investments highlights a strong commitment to expanding its domestic operations in the U.S. |